QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress expands health subsidies, tightens PBM secrecy rules

H.R. 6501 — Bipartisan Health Insurance Affordability Act · Filed by Brian Fitzpatrick (R-PA) · 22 cosponsors · Introduced Dec 9, 2025 · Referred to committee

55%
Transparency
Typical bill: 82%
28/100
Hidden-provision risk
Typical bill: 15/100
High concernHealthcare Affordability & PBM Regulation

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill extends and expands health insurance premium subsidies for lower-income Americans through 2027, tightens fraud controls on health insurance agents and brokers, and imposes new transparency and accountability requirements on pharmacy benefit managers (PBMs) in Medicare Part D. Citizens earning up to 700% of the poverty line (vs. the current 400% cap) become eligible for subsidies; agents/brokers face civil and criminal penalties for providing false enrollment information; and PBMs must disclose detailed pricing, rebate, and compensation data to Medicare and plan sponsors.

Why we flagged it

The bill's core function is twofold: (1) expanding Affordable Care Act premium tax credits for lower-income households, and (2) imposing strict transparency and anti-fraud requirements on pharmacy benefit managers and health insurance agents. Both are regulatory/consumer-protection measures, not tax cuts or subsidies to industry.

What the text implies

  • PBM transparency requirements may force disclosure of affiliate pharmacy profits and rebate-sharing arrangements, potentially exposing conflicts of interest that have inflated drug costs; this could trigger litigation or regulatory action against major PBMs.
  • The 'bona fide service fee' definition and prohibition on price-contingent compensation may disrupt existing PBM revenue models and affiliate pharmacy arrangements, particularly for mail-order and specialty pharmacy operations.

The full analysis lists 5 implications of this text.

Who stands to gain

Lower-income households (premium subsidy expansion); Medicare Part D beneficiaries (PBM transparency may reduce drug costs); Health insurance plans (fraud reduction, agent accountability)

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record